Skip to content
Life Sciences Series A Founded 2013

Samplix ApS

Provider of microfluidics-based technology for the encapsulation of microbial and mammalian cells. The company has developed a microfluidics instrument called Xdrop that encapsulates the target living cells, DNA fragments, or organelles together with the assay chemistry is highly stable double-emulsion droplets. It has applications for cell reaction screening and verification of gene edits. The company was founded…

📍 Birkerod, Denmark · Genomics,

Funding snapshot

Last roundSeries A
Amount$13M
Date30 March 2023
Total raised$13M
Valuation19,034,122 (Dec 28, 2020)
Team size31

About

Provider of microfluidics-based technology for the encapsulation of microbial and mammalian cells. The company has developed a microfluidics instrument called Xdrop that encapsulates the target living cells, DNA fragments, or organelles together with the assay chemistry is highly stable double-emulsion droplets. It has applications for cell reaction screening and verification of gene edits. The company was founded in 2013 and headquartered in Birkerod, Denmark. It has raised $12.8M in series a funding, with backing from EIC Fund, Europa, Fjord Capital Partners, Jersey Finance. The company operates in the Life Sciences - Genomics, Life Sciences - Life Sciences Platforms and Tools space.

Business model

Genomics > Enabling Technologies > Instrument Systems > Nucleic Acid Analysis > Amplification > Whole Genome Amplification,

Life Sciences Platforms and Tools > Instruments > Microfluidics

Institutional investors

EIC Fund Europa Fjord Capital Partners Jersey Finance Christopher John Nicholas Braden Georg Von Werz

Latest coverage

No articles yet.

Raising like Samplix ApS?

Analyze your pitch deck before your next raise.

Analyze My Deck →